Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Days Payable Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Days Payable vs Drug Manufacturers Industry
United Laboratories International Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (STU:UNJ) has a Days Payable of 247.66 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on United Laboratories International Holdings and its competitors. This is 25% above median its historical median of 197.79. Over the past decade, United Laboratories International Holdings' Days Payable has ranged from 162.45 to 271.99. According to the industry distribution chart, United Laboratories International Holdings ranks #109 out of 927 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is United Laboratories International Holdings' Days Payable too high?
United Laboratories International Holdings' current Days Payable of 247.66 is 25% above median its 10-year median of 197.79. Over the past 10 years, this metric has ranged from a low of 162.45 to a high of 271.99. The Drug Manufacturers industry median Days Payable is 90.38. United Laboratories International Holdings' value of 247.66 is 174% above this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #109 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Laboratories International Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #109 out of 927 companies for Days Payable. This places United Laboratories International Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. United Laboratories International Holdings' value of 247.66 is 174% above this benchmark. Historically, United Laboratories International Holdings' own Days Payable has ranged from 162.45 to 271.99 over the past decade. While the company's 10-year median is 197.79 vs. the industry median of 90.38, United Laboratories International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Days Payable of 247.66 is 174% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Days Payable is 247.66, which is 25% above median its own 10-year median of 197.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (STU:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.93, compared to a current price of €1.00 — trading 7% above its estimated fair value. The current Days Payable is 247.66, which is 25% above median its 10-year median of 197.79 and 174% above the Drug Manufacturers industry median of 90.38. United Laboratories International Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For United Laboratories International Holdings (STU:UNJ), the current Days Payable is 247.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (STU:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be overvalued.
The current stock price of €1.00 is trading 7% above its estimated GF Value™ of €0.93.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for STU:UNJ:
Days Payable: 247.66 (25% above median its 10-year median of 197.79)
GF Value™: €0.93 vs. price of €1.00 (7% above fair value)
Industry Position: 174% above the Drug Manufacturers median (#109 of 927)
No single metric tells the full story. See the STU:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
65GF Score
Get the complete analysis for STU:UNJ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNJ has been successfully added to your 
